Inloggad som:
MiMir-studien (89Zr-Atezolizumab PET/CT)
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
MiMir-studien (89Zr-Atezolizumab PET/CT)
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer
PLACEHOLDER
Trippelnegativ bröstcancer som är PDL1-positiv på PET/CT med 89Zr-Atezolizumab eller på tumöranalys får Atezolizumab som 1st line behandling
Mer information om studien för vårdgivare
Patients with metastatic triple negative breast cancer (mTNBC), defined by pathological criteria: ER expression <10%, PgR expression <10%, HER2 negative,on the primary tumour or a metastatic biopsy.Measurable disease according to RECIST v1.1 (7).At least one metastatic lesion accessible for biopsy.
Previous treatment with chemotherapy or targeted therapy for mTNBC. Radiation therapy and previous chemotherapy (including taxanes) in the context of curative therapy
Contraindications for PET/CT as defined for clinical practice
Other malignancy diagnosed within the last five years.
Behandling
Fas 2
Palliativ
Akademisk
Studien ändrades senast av: studyjohanna (2024-04-21)